N@N

Inhibitex Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (

_{//health-fitness.news-articles.net/content/2010/ .. association-for-the-study-of-liver-diseases.html}
^{Published in Health and Fitness on Tuesday, November 2nd 2010 at 17:00 GMT by Market Wire}  

ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ: INHX) announced today that three posters describing preclinical data on INX-189, the Companya™s nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61^st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstracts can be viewed at the AASLD website at [ www.aasld.org ].

"Metabolite Characterization of INX-189, a Potent HCV Inhibitor, in Fresh Human Primary Hepatocytes and Human Liver and Kidney Cell Lines"

The three posters will be presented during the HCV Therapy: Preclinical and Early Clinical Development Poster Session, today, November 2, 2010, from 7:00 am - 12:00 pm. The posters are as follows:

• #1888; Kolykhalov et al., aCharacterization of in vitro selected Hepatitis C Virus Replicon Mutants Resistant to the Phosphoramidate Analog of 2a™-C-Methylguanosine, INX-189a
• #1874; Hall et al., aMetabolite Characterization of INX-189, a Potent HCV Inhibitor, in Fresh Human Primary Hepatocytes and Human Liver and Kidney Cell Linesa
• #1889; Vernachio, et al. aIn Vitro and In Vivo Metabolism of INX-189, a Potent HCV Inhibitor, in Rat and Cynomolgus Monkey Hepatocytesa

About Inhibitex

Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM^® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex^® and MSCRAMM^® are registered trademarks of Inhibitex, Inc.